1
|
Zhang C, Sun C, Zhao Y, Ye B, Yu G. Signaling pathways of liver regeneration: Biological mechanisms and implications. iScience 2024; 27:108683. [PMID: 38155779 PMCID: PMC10753089 DOI: 10.1016/j.isci.2023.108683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2023] Open
Abstract
The liver possesses a unique regenerative ability to restore its original mass, in this regard, partial hepatectomy (PHx) and partial liver transplantation (PLTx) can be executed smoothly and safely, which has important implications for the treatment of liver disease. Liver regeneration (LR) can be the very complicated procedure that involves multiple cytokines and transcription factors that interact with each other to activate different signaling pathways. Activation of these pathways can drive the LR process, which can be divided into three stages, namely, the initiation, progression, and termination stages. Therefore, it is important to investigate the pathways involved in LR to elucidate the mechanism of LR. This study reviews the latest research on the key signaling pathways in the different stages of LR.
Collapse
Affiliation(s)
- Chunyan Zhang
- State Key Laboratory Cell Differentiation and Regulation, Henan International Joint Laboratory of Pulmonary Fibrosis, Henan Center for Outstanding Overseas Scientists of Pulmonary Fibrosis, College of Life Science, Institute of Biomedical Science, Henan Normal University, Xinxiang, Henan, China
| | - Caifang Sun
- State Key Laboratory Cell Differentiation and Regulation, Henan International Joint Laboratory of Pulmonary Fibrosis, Henan Center for Outstanding Overseas Scientists of Pulmonary Fibrosis, College of Life Science, Institute of Biomedical Science, Henan Normal University, Xinxiang, Henan, China
| | - Yabin Zhao
- State Key Laboratory Cell Differentiation and Regulation, Henan International Joint Laboratory of Pulmonary Fibrosis, Henan Center for Outstanding Overseas Scientists of Pulmonary Fibrosis, College of Life Science, Institute of Biomedical Science, Henan Normal University, Xinxiang, Henan, China
| | - Bingyu Ye
- State Key Laboratory Cell Differentiation and Regulation, Henan International Joint Laboratory of Pulmonary Fibrosis, Henan Center for Outstanding Overseas Scientists of Pulmonary Fibrosis, College of Life Science, Institute of Biomedical Science, Henan Normal University, Xinxiang, Henan, China
| | - GuoYing Yu
- State Key Laboratory Cell Differentiation and Regulation, Henan International Joint Laboratory of Pulmonary Fibrosis, Henan Center for Outstanding Overseas Scientists of Pulmonary Fibrosis, College of Life Science, Institute of Biomedical Science, Henan Normal University, Xinxiang, Henan, China
| |
Collapse
|
2
|
Yang X, Fan X, Feng J, Fan T, Li J, Huang L, Wan L, Yang H, Li H, Gong J, Zhang Y, Gao Q, Zheng F, Xu L, Lin H, Zhang D, Song H, Wang Y, Ma X, Sun Z, Cao C, Yang X, Zhong H, Fang Y, Wei C. GP73 blockade alleviates abnormal glucose homeostasis in diabetic mice. J Mol Endocrinol 2023; 70:JME-22-0103. [PMID: 36394986 DOI: 10.1530/jme-22-0103] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/04/2022] [Accepted: 11/15/2022] [Indexed: 11/18/2022]
Abstract
Golgi protein 73 (GP73), also called Golgi membrane protein 1 (GOLM1), is a resident Golgi type II transmembrane protein and is considered as a serum marker for the detection of a variety of cancers. A recent work revealed the role of the secreted GP73 in stimulating liver glucose production and systemic glucose homeostasis. Since exaggerated hepatic glucose production plays a key role in the pathogenesis of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), GP73 may thus represent a potential therapeutic target for treating diabetic patients with pathologically elevated levels. Here, in this study, we found that the circulating GP73 levels were significantly elevated in T2DM and positively correlated with hemoglobin A1c. Notably, the aberrantly upregulated GP73 levels were indispensable for the enhanced protein kinase A signaling pathway associated with diabetes. In diet-induced obese mouse model, GP73 siRNA primarily targeting liver tissue was potently effective in alleviating abnormal glucose metabolism. Ablation of GP73 from whole animals also exerted a profound glucose-lowering effect. Importantly, neutralizing circulating GP73 improved glucose metabolism in streptozotocin (STZ) and high-fat diet/STZ-induced diabetic mice. We thus concluded that GP73 was a feasible therapeutic target for the treatment of diabetes.
Collapse
Affiliation(s)
- Xiaopan Yang
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China
| | - Xiaojing Fan
- Department of Endocrinology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
| | - Jiangyue Feng
- Beijing Sungen Biomedical Technology Co. Ltd., Beijing, China
| | - Tinghui Fan
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China
| | - Jingfei Li
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China
- Institute of Physical Science and Information Technology, Anhui University, Hefei, China
| | - Linfei Huang
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China
| | - Luming Wan
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China
| | - Huan Yang
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China
| | - Huilong Li
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China
| | - Jing Gong
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China
| | - Yanhong Zhang
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China
| | - Qi Gao
- Beijing Sungen Biomedical Technology Co. Ltd., Beijing, China
| | - Fei Zheng
- Beijing Sungen Biomedical Technology Co. Ltd., Beijing, China
| | - Lei Xu
- Beijing Sungen Biomedical Technology Co. Ltd., Beijing, China
| | - Haotian Lin
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China
| | - Dandan Zhang
- Department of Laboratory, the Third Medical Center of Chinese PLA General Hospital, Beijing, China
- Department of Laboratory, General Hospital of Armed Police Forces, Anhui Medical University, Hefei, China
| | - Hongbin Song
- Department of Laboratory, the Third Medical Center of Chinese PLA General Hospital, Beijing, China
- Department of Laboratory, General Hospital of Armed Police Forces, Anhui Medical University, Hefei, China
| | - Yufei Wang
- Department of Laboratory, the Third Medical Center of Chinese PLA General Hospital, Beijing, China
- Department of Laboratory, General Hospital of Armed Police Forces, Anhui Medical University, Hefei, China
| | - Xueping Ma
- Department of Laboratory, the Third Medical Center of Chinese PLA General Hospital, Beijing, China
- Department of Laboratory, General Hospital of Armed Police Forces, Anhui Medical University, Hefei, China
| | - Zhiwei Sun
- Beijing Sungen Biomedical Technology Co. Ltd., Beijing, China
| | - Cheng Cao
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China
| | - Xiaoli Yang
- Department of Laboratory, the Third Medical Center of Chinese PLA General Hospital, Beijing, China
- Department of Laboratory, General Hospital of Armed Police Forces, Anhui Medical University, Hefei, China
| | - Hui Zhong
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China
| | - Yi Fang
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China
- Department of Endocrinology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
| | - Congwen Wei
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China
| |
Collapse
|
3
|
Liu MY, Huang L, Wu JF, Zhang HB, Ai WB, Zhang RT. Possible roles of Golgi protein-73 in liver diseases. Ann Hepatol 2022; 27:100720. [PMID: 35577277 DOI: 10.1016/j.aohep.2022.100720] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Revised: 04/13/2022] [Accepted: 04/19/2022] [Indexed: 02/04/2023]
Abstract
Golgi protein 73 (also known as GP73 or GOLPH2) is a transmembrane glycoprotein present in the Golgi apparatus. In diseased states, GP73 is expressed by hepatocytes rather than by bile duct epithelial cells. Many studies have reported that serum GP73 (sGP73) is a marker for hepatocellular carcinoma (HCC). For HCC diagnosis, the sensitivities of sGP73 were higher than that of other markers but the specificities were lower. Considering that the concentration of GP73 is consistent with the stage of liver fibrosis and cirrhosis, some studies have implied that GP73 may be a marker for liver fibrosis and cirrhosis. Increased sGP73 levels may result from hepatic inflammatory activity. During liver inflammation, GP73 facilitates liver tissue regeneration. By summarizing the studies on GP73 in liver diseases, we wish to focus on the mechanism of GP73 in diseases.
Collapse
Affiliation(s)
- Meng-Yuan Liu
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University; Medical College, China Three Gorges University; Institute of Organ Fibrosis and Targeted Drug Delivery, China Three Gorges University, Yichang, China
| | - Lu Huang
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University; Medical College, China Three Gorges University; Institute of Organ Fibrosis and Targeted Drug Delivery, China Three Gorges University, Yichang, China
| | - Jiang-Feng Wu
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University; Medical College, China Three Gorges University; Institute of Organ Fibrosis and Targeted Drug Delivery, China Three Gorges University, Yichang, China
| | - Hong-Bing Zhang
- Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Wen-Bing Ai
- The Yiling Hospital of Yichang, 31 Donghu Road, Yi Ling District, Yichang 443100, Hubei, China.
| | - Rui-Tao Zhang
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University; Medical College, China Three Gorges University; Institute of Organ Fibrosis and Targeted Drug Delivery, China Three Gorges University, Yichang, China.
| |
Collapse
|